The biotechnology company InSphero, headquartered in Schlieren in the canton of Zurich, Switzerland, has agreed a partnership with the New York research organization Breakthrough T1D (T1D) and the Center for Diabetes Research at Université Libre de Bruxelles (ULB) in Belgium. This collaboration, financed by Breakthrough T1D, aims to develop novel treatment strategies for T1D, focusing on protecting and preserving the vital insulin-producing beta cells in the pancreas, further details of which can be found in a press release.
Type 1 diabetes is a serious disease in which the immune system mistakenly attacks the body’s beta cells. This ultimately results in the body not producing enough insulin, as InSphero writes in a press release. The innovative approach of the new collaboration aims to protect these cells from immune system attack by focusing on the body’s own beta cell mechanisms. According to the press release, Decio L. Eizirik, who is an expert in beta cell research at the ULB Center for Diabetes Research, is InSphero's scientific partner for this project.
“Unlike traditional approaches that focus solely on the immune system, our strategy addresses the misguided dialogue between the immune system and beta cells in T1D”, comments Burcak Yesildag, Vice President of Islet Biology at InSphero.
By bringing together the technology developed by InSphero with the scientific expertise of ULB, it is hoped that “significant breakthroughs in the fight against T1D” can be achieved, as Jay Tinklepaugh, Senior Scientist at Breakthrough T1D, explains in the press release.
InSphero is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH). The company is headquartered at the Bio-Technopark Schlieren-Zurich. ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space